Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
2 Acute myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
3 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
4 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
5 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
6 Adrenergic signaling in cardiomyocytes 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 1件: 280 💬
7 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
10 Alcoholic liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
11 Alcoholism 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
12 Alcoholism 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
13 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
14 Alzheimer disease 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
15 Alzheimer disease 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
16 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
17 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
18 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
19 AMPK signaling pathway 💬
 1件: ADRA1A 💬 D08207 💬 Methylergometrine 1件: 280 💬
20 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
21 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
22 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
23 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
24 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
25 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
26 Apelin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
27 Apelin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
28 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
29 Apoptosis 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
30 Apoptosis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
31 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
32 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
33 Autophagy - animal 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
34 Autophagy - animal 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
35 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
36 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
37 B cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
38 B cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
39 Bile secretion 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
40 Bladder cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
41 Bladder cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
42 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
43 Breast cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
44 Breast cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
45 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
46 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
47 Calcium signaling pathway 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 1件: 280 💬
48 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
49 cAMP signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
50 cAMP signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
51 Cellular senescence 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
52 Cellular senescence 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
53 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
54 Central carbon metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
55 Central carbon metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
56 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
57 cGMP-PKG signaling pathway 💬
 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 D08207 💬 Methylergometrine 1件: 280 💬
58 cGMP-PKG signaling pathway 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D00514 💬 Dexmedetomidine 14件:  2 ,  4 ,  6 , 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
59 cGMP-PKG signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
60 cGMP-PKG signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
61 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
62 Chemical carcinogenesis - reactive oxygen species 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
63 Chemical carcinogenesis - reactive oxygen species 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
64 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
65 Chemical carcinogenesis - receptor activation 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
66 Chemical carcinogenesis - receptor activation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
67 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
68 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
69 Chemokine signaling pathway 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
70 Chemokine signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
71 Choline metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
72 Choline metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
73 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
74 Cholinergic synapse 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
75 Cholinergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
76 Chronic myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
77 Chronic myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
78 Colorectal cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
79 Colorectal cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
80 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
81 Complement and coagulation cascades 💬
 1件: SERPINC1 💬 D07510 💬 Heparin 11件: 47, 60, 70, 84, 107, 224, 226, 280, 299, 316, 317 💬
82 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
83 Cushing syndrome 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
84 Cushing syndrome 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
85 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
86 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
87 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
88 EGFR tyrosine kinase inhibitor resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
89 EGFR tyrosine kinase inhibitor resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
90 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
91 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
92 Endocrine resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
93 Endocrine resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
94 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
95 Endometrial cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
96 Endometrial cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
97 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
98 ErbB signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
99 ErbB signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
100 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
101 Estrogen signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
102 Estrogen signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
103 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
104 Fc epsilon RI signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
105 Fc epsilon RI signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
106 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
107 Fc gamma R-mediated phagocytosis 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
108 Fc gamma R-mediated phagocytosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
109 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
110 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
111 Focal adhesion 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
112 Focal adhesion 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
113 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
114 FoxO signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
115 FoxO signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
116 Gap junction 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
117 Gap junction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
118 Gastric cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
119 Gastric cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
120 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
121 Glioma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
122 Glioma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
123 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
124 GnRH secretion 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
125 GnRH secretion 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
126 GnRH signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
127 GnRH signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
128 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
129 Growth hormone synthesis, secretion and action 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
130 Growth hormone synthesis, secretion and action 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
131 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
132 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
133 Hepatitis B 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
134 Hepatitis B 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
135 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
136 Hepatitis C 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
137 Hepatitis C 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
138 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
139 Hepatocellular carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
140 Hepatocellular carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
141 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
142 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
143 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
144 HIF-1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
145 HIF-1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
146 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
147 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
148 Human cytomegalovirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
149 Human cytomegalovirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
150 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
151 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
152 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
153 Human immunodeficiency virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
154 Human immunodeficiency virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
155 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
156 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
157 Human papillomavirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
158 Human papillomavirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
159 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
160 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
161 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
162 Human T-cell leukemia virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
163 Human T-cell leukemia virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
164 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
165 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
166 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
167 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
168 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
169 Influenza A 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
170 Influenza A 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
171 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
172 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
173 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
174 Insulin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
175 Insulin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
176 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
177 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
178 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
179 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
180 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
181 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
182 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
183 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
184 Lipid and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
185 Long-term depression 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
186 Long-term depression 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
187 Long-term potentiation 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
188 Long-term potentiation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
189 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
190 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
191 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
192 MAPK signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
193 MAPK signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
194 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
195 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
196 Melanogenesis 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
197 Melanogenesis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
198 Melanoma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
199 Melanoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
200 Metabolic pathways 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
201 MicroRNAs in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
202 MicroRNAs in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
203 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
204 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
205 Morphine addiction 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
206 mTOR signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
207 mTOR signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
208 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
209 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
210 Natural killer cell mediated cytotoxicity 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
211 Natural killer cell mediated cytotoxicity 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
212 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
213 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
214 Neuroactive ligand-receptor interaction 💬
 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 D08207 💬 Methylergometrine 1件: 280 💬
215 Neuroactive ligand-receptor interaction 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D00514 💬 Dexmedetomidine 14件:  2 ,  4 ,  6 , 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
216 Neuroactive ligand-receptor interaction 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
217 Neurotrophin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
218 Neurotrophin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
219 Neutrophil extracellular trap formation 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
220 Neutrophil extracellular trap formation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
221 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
222 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
223 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
224 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
225 Non-small cell lung cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
226 Non-small cell lung cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
227 Oocyte meiosis 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
228 Oocyte meiosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
229 Osteoclast differentiation 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
230 Osteoclast differentiation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
231 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
232 Oxytocin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
233 Oxytocin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
234 Pancreatic cancer 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
235 Pancreatic cancer 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
236 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
237 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
238 Parathyroid hormone synthesis, secretion and action 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
239 Parathyroid hormone synthesis, secretion and action 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
240 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
241 Pathways in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
242 Pathways in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
243 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
244 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
245 Pathways of neurodegeneration - multiple diseases 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
246 Pathways of neurodegeneration - multiple diseases 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
247 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
248 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
249 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
250 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
251 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
252 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
253 Phospholipase D signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
254 Phospholipase D signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
255 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
256 PI3K-Akt signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
257 PI3K-Akt signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
258 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
259 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
260 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
261 Progesterone-mediated oocyte maturation 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
262 Progesterone-mediated oocyte maturation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
263 Prolactin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
264 Prolactin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
265 Prostate cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
266 Prostate cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
267 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
268 Proteoglycans in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
269 Proteoglycans in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
270 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
271 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
272 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
273 Rap1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
274 Rap1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
275 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
276 Ras signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
277 Ras signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
278 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
279 Regulation of actin cytoskeleton 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
280 Regulation of actin cytoskeleton 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
281 Relaxin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
282 Relaxin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
283 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
284 Renal cell carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
285 Renal cell carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
286 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
287 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
288 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
289 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
290 Salivary secretion 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 1件: 280 💬
291 Salmonella infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
292 Salmonella infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
293 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
294 Serotonergic synapse 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
295 Serotonergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
296 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
297 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
298 Signaling pathways regulating pluripotency of stem cells 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
299 Signaling pathways regulating pluripotency of stem cells 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
300 Sphingolipid signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
301 Sphingolipid signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
302 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
303 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
304 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
305 T cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
306 T cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
307 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
308 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
309 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
310 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
311 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
312 Thyroid cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
313 Thyroid cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
314 Thyroid hormone signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
315 Thyroid hormone signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
316 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
317 TNF signaling pathway 💬
 1件: MAP2K1 💬 D10405 💬 Cobimetinib 1件: 280 💬
318 TNF signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
319 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
320 Toll-like receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
321 Toll-like receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
322 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
323 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
324 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
325 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
326 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
327 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
328 Vascular smooth muscle contraction 💬
 3件: ADRA1A, ADRA1B, ADRA1D 💬 D08207 💬 Methylergometrine 1件: 280 💬
329 Vascular smooth muscle contraction 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
330 Vascular smooth muscle contraction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
331 VEGF signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
332 VEGF signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
333 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
334 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
335 Yersinia infection 💬
 2件: MAP2K1, MAP2K2 💬 D10405 💬 Cobimetinib 1件: 280 💬
336 Yersinia infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
337 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ